Article

On the Web: Shared Decision-Making

Shared decision-making is a collaborative process for building relationships between patients and providers.

Shared decision making is a collaborative process for building relationships between patients and providers, using both scientific evidence and the patient’s values and preferences to make decisions about care. While by no means a new idea, it has had some difficulty gaining traction. A recent editorial in the New England Journal of Medicine noted that “A sleeper provision of the Affordable Care Act (ACA) encourages greater use of shared decision making in healthcare.”

Among the benefits of shared decision making:

• The process itself involves a dialogue with your provider, giving you the opportunity to ask questions. You can ask about your prognosis—if you want to know.

• It will help you get accurate information and ensure that you know the risks and benefits of treatment options. This is especially helpful if there is more than one approach, without one that is clearly superior.

• It will allow you to share your values with your provider. You might want the most aggressive treatment possible, or your quality of life during treatment may be more important to you. This decision should be yours, not your doctor’s.

• In the long run, it will reduce the cost of healthcare. Studies have shown that some people choose more conservative and therefore less-expensive options, and that the overall savings could be substantial.

To help guide the conversation, researchers have developed what are called “patient decision aids.” Created with patient input, they are well-validated and exist for cardiovascular disease, osteoporosis, diabetes, statin use and prostate cancer, among other conditions. Although fewer have been developed for other cancers, decision support interventions such as question prompt lists and recording of conversations have been found similarly effective. A useful tool is available from the Agency for Healthcare Research and Quality (effectivehealthcare.ahrq.gov/index.cfm/options/tool).

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content